KR850000240A - 경구용 당뇨병 치료제 제형의 제조방법 - Google Patents
경구용 당뇨병 치료제 제형의 제조방법 Download PDFInfo
- Publication number
- KR850000240A KR850000240A KR1019840003188A KR840003188A KR850000240A KR 850000240 A KR850000240 A KR 850000240A KR 1019840003188 A KR1019840003188 A KR 1019840003188A KR 840003188 A KR840003188 A KR 840003188A KR 850000240 A KR850000240 A KR 850000240A
- Authority
- KR
- South Korea
- Prior art keywords
- basic
- active substance
- excipient
- group
- benzoic acid
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 7
- 238000009472 formulation Methods 0.000 title claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 title claims 5
- 230000001225 therapeutic effect Effects 0.000 title claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 10
- 239000013543 active substance Substances 0.000 claims 8
- 238000000034 method Methods 0.000 claims 7
- 239000005711 Benzoic acid Substances 0.000 claims 5
- 239000002904 solvent Substances 0.000 claims 5
- 230000002378 acidificating effect Effects 0.000 claims 4
- -1 octamethyleneimino group Chemical group 0.000 claims 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- 239000011149 active material Substances 0.000 claims 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Polymers FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 claims 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims 1
- 229940100389 Sulfonylurea Drugs 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 229910021529 ammonia Inorganic materials 0.000 claims 1
- 235000010233 benzoic acid Nutrition 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 238000001704 evaporation Methods 0.000 claims 1
- 150000002191 fatty alcohols Chemical class 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 claims 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical compound OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/6574—Esters of oxyacids of phosphorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
- Steroid Compounds (AREA)
Abstract
내용 없음.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 공복상태인 건강인에게 실시예 2,6,8에 상응하는 제형을 투여하여 그의 혈당치를 비교한 것이다.
Claims (8)
- 용매중의 폴리비닐피룰리돈 및 임의의 기타 가용화제의 존재하에서, 산성적으로 반응하는 활성물질을 염기성 부형제의 보조로 용해시키거나, 양(兩)성적으로 반응하는 활성물질을 염기성 또는 산성 부형제의 보조로 용해시키거나, 또는 염기성적으로 반응하는 활성물질을 산성 부형제의 보조로 용해시키고, 이때 염기성 또는 산성 부형제의 대한 활성물질의 몰비가 1:1미만이어야 하며, 생성된 용액을 증발시켜 건고시킨 다음, 다른 부형제로 임의로 더욱 처리하여 목적하는 제형을 제조함을 특징으로 하여 당뇨병 치료작용을 지닌 활성물질을 함유하는 경구용 제형을 제조하는 방법.
- 제1항에 있어서 경구용의 당뇨병 치료작용을 지닌 설포닐우레아를 사용함을 특징으로 하는 방법.
- 제1항에 있어서, 사용된 경구용의 당뇨병 치료작용을 지닌 활성물질이 a) 일반식(1)의 4-[2-아로일아미노)에틸]-벤조산이거나 b) 일반식(Ⅱ)의 치환된 4-(아르알킬아미노카보닐-메틸)-벤조산이거나 또는 이들 물질의 혼합물임을 특징으로 하는 방법.상기식에서, R1은 할로겐원자, 바람직하게는 염소원자를 나타내고, R2는 탄소수 1 내지 3의 알콕시그룹, 또는 피페리딘-1-일 또는 옥타메틸렌이미노 그룹을 나타내며, R3는 탄소수 1 내지 4의 알킬그룹, 바람직하게는 n-프로필그룹, 또는 페닐그룹을 나타내고, R4는 피페리딘-1-일, 피롤리딘-1-일 또는 헥사메틸렌이미노그룹을 나타내며, R5는 수소 또는 할로겐원자, 또는 메틸 도는 메톡시그룹을 나타낸다.
- 제1항에 있어서, 1개 이상의 염기성 부형제를 첨가하여, 활성물질 또는 활성물질들을 용매중에 용해시키고, 이때 염기성 부형제에 대한 활성물질의 몰비가 1:1미만이어야 하며, 여기에 폴리비닐피롤리돈 및 임의의 기타 가용화제를 용해시키고, 이 용액을 증발 건고시킨 다음 임의로 기타 부형제로 더욱 처리하여 목적하는 제제를 얻음을 특징으로 하여 글리퀴돈 및/또는 4-[2-(5-클로로-2-옥타메틸렌이미노-벤조일아미노)에틸]벤조산 및/또는 4-[N-(1α-페닐-2-피페리디노-벤질)-아미노카보닐메틸]-벤조산 및/또는 4-[[1-(2-피페리디노-페닐)-1-부틸]-아미노카보닐케틸]-벤조산 및 용성담체를 함유하는 제1항에서와 같은 경구용의 당뇨병 치료작용을 지닌 제형의 제조방법.
- 제1항 내지 4항중 어느 하나에 있어서, 염기성 또는 산성 부형에 대한 활성물질의 몰비를 1:1.1내지 1:10으로 유지하며, 이때 또한 염기성 부형제의 혼합물을 사용할 수 있음을 특징으로 하는 방법.
- 제1항 내지 5항중 어느 하나에 있어서, 활성물질 또는 활성물질들의 혼합물과 폴리비닐피롤리돈이 1:1내지 1:10중량부의 비율로 함유됨을 특징으로 하는 방법.
- 제1항 내지 6항중 어느 하나에 있어서, 사용된 기타의 가용화제가 폴리옥시에틸렌 폴리옥시프로필렌 중합체, 폴리에틸렌글리콜, 폴리에톡실화 소르비탄모노올레이트, 소르비톨, 글리세롤폴리-에틸렌 글리콜옥 시스테아레이트, 폴리옥시에틸렌 지방알코올 에테르 또는 이들 물질의 혼합물임을 특징으로 하는 방법.
- 제1항 내지 6항중 어느 하나에 있어서, 사용된 염기가 수산화나트륨 용액, 수산화칼륨 용액, 암모니아3급인산나트륨, 디에탄올아미, L-리신, 에틸렌디아민, 또는 N-메틸-글루카민임을 특징으로 하는 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19833320582 DE3320582A1 (de) | 1983-06-08 | 1983-06-08 | Gliquidonhaltige zubereitungsformen und verfahren zu ihrer herstellung |
| DEP3320582.5 | 1983-06-08 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR850000240A true KR850000240A (ko) | 1985-02-26 |
| KR910004571B1 KR910004571B1 (ko) | 1991-07-06 |
Family
ID=6200885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019840003188A KR910004571B1 (ko) | 1983-06-08 | 1984-06-07 | 경구용 당뇨병치료 제제를 제조하는 방법 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US4696815A (ko) |
| EP (1) | EP0128483B1 (ko) |
| JP (1) | JPS6069038A (ko) |
| KR (1) | KR910004571B1 (ko) |
| AT (1) | ATE56365T1 (ko) |
| AU (1) | AU563642B2 (ko) |
| CA (1) | CA1228299A (ko) |
| DD (1) | DD224216A5 (ko) |
| DE (2) | DE3320582A1 (ko) |
| DK (1) | DK162019C (ko) |
| ES (1) | ES8506446A1 (ko) |
| FI (1) | FI85217C (ko) |
| GB (1) | GB2142236B (ko) |
| GR (1) | GR82362B (ko) |
| HK (1) | HK72387A (ko) |
| HU (1) | HU193932B (ko) |
| IE (1) | IE57793B1 (ko) |
| IL (1) | IL72034A (ko) |
| MY (1) | MY100795A (ko) |
| NO (1) | NO168628C (ko) |
| NZ (1) | NZ208417A (ko) |
| PH (1) | PH24567A (ko) |
| PT (1) | PT78710B (ko) |
| SG (1) | SG48187G (ko) |
| ZA (1) | ZA844296B (ko) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3320583A1 (de) * | 1983-06-08 | 1984-12-13 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung |
| DE3320582A1 (de) * | 1983-06-08 | 1984-12-13 | Dr. Karl Thomae Gmbh, 7950 Biberach | Gliquidonhaltige zubereitungsformen und verfahren zu ihrer herstellung |
| US5312924A (en) * | 1983-12-30 | 1994-05-17 | Dr. Karl Thomae Gmbh | Phenylacetic acid benzylamides |
| US4819238A (en) * | 1987-10-26 | 1989-04-04 | Hughes Aircraft Company | Wide band free electron laser with variable phase and frequency |
| US5258185A (en) * | 1989-08-23 | 1993-11-02 | Bauer Kurt H | Highly active, rapidly absorbable formulations of glibenclamide, processes for the production thereof and their use |
| US5024843A (en) * | 1989-09-05 | 1991-06-18 | Alza Corporation | Oral hypoglycemic glipizide granulation |
| CH678920A5 (ko) * | 1989-11-14 | 1991-11-29 | Gergely Gerhard | |
| US5773025A (en) | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
| US5455046A (en) * | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
| US6726930B1 (en) * | 1993-09-09 | 2004-04-27 | Penwest Pharmaceuticals Co. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
| IL123505A (en) * | 1996-07-08 | 2004-12-15 | Penwest Pharmaceuticals Compan | Sustained release matrix for high-dose insoluble drugs |
| WO1999004818A1 (fr) * | 1997-07-24 | 1999-02-04 | Eisai Co., Ltd. | Composition pour preparation pharmaceutique et son procede de production |
| US6056977A (en) | 1997-10-15 | 2000-05-02 | Edward Mendell Co., Inc. | Once-a-day controlled release sulfonylurea formulation |
| US6099859A (en) | 1998-03-20 | 2000-08-08 | Andrx Pharmaceuticals, Inc. | Controlled release oral tablet having a unitary core |
| US6099862A (en) * | 1998-08-31 | 2000-08-08 | Andrx Corporation | Oral dosage form for the controlled release of a biguanide and sulfonylurea |
| MXPA01005370A (es) * | 1999-09-30 | 2004-05-14 | Penwest Pharmaceuticals Co | Sistema de matriz de liberacion sostenida para farmacos altamente solubles. |
| US6703045B2 (en) | 2001-08-21 | 2004-03-09 | Council Of Scientific & Industrial Research | Composition and method for maintaining blood glucose level |
| KR20040044992A (ko) * | 2001-09-28 | 2004-05-31 | 썬 파마슈티컬 인더스트리스 리미티드 | 당뇨병 치료용 투여형태 |
| AU2002350719A1 (en) * | 2002-11-29 | 2004-06-23 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base |
| AU2003269480A1 (en) * | 2003-09-10 | 2005-03-29 | Biocon Limited | Phosphoric acid salt of (s)-(+)-2-ethoxy-4-{(3-methyl-1-(2-piperidin-1-yl-phenyl)-butylcarbamoyl)-methyl}-benzoic acid |
| AU2003269481A1 (en) * | 2003-09-10 | 2005-03-29 | Biocon Limited | (s)-(+)-2-ethoxy-4-{(3-methyl-1-(2-piperidin-1-yl-phenyl)-butylcarbamoyl)-methyl}-benzoic acid sodium salt |
| TR200704897A1 (tr) | 2007-07-13 | 2009-02-23 | Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� | Uzatılmış salım sağlayan gliklazid formülasyonları@ |
| EP2181705A1 (en) | 2008-10-31 | 2010-05-05 | Disphar International B.V. | Sustained-release formulation of gliclazide |
| TR201107482A1 (tr) | 2010-12-21 | 2012-07-23 | Sanovel İlaç San.Ve Ti̇c.A.Ş. | Vildagliptin ve gliklazidin iki tabakalı kombinasyon kompozisyonu. |
| EP2468268B1 (en) | 2010-12-21 | 2017-12-13 | Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi | Combination composition of vildagliptin and gliclazide |
| TR201103946A1 (tr) | 2011-04-22 | 2012-11-21 | Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ | Kontrollü salım sağlayan gliklazid formülasyonları. |
| IN2014CN04119A (ko) | 2011-11-15 | 2015-07-10 | Reddys Lab Ltd Dr | |
| WO2014128116A1 (en) | 2013-02-19 | 2014-08-28 | Sanovel Ilac Sanayi Ve Ticaret A.S. | A production process for gliclazide formulations |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1187259A (en) * | 1967-10-23 | 1970-04-08 | Hexachimie | New Aminoalkyl Esters of 2-Anilino-Nicotinic Acids and process for their manufacture |
| US3668215A (en) * | 1967-11-25 | 1972-06-06 | Bayer Ag | Aryl-sulphonyl-semicarbazides containing heterocyclic acylamino groups |
| NL138933B (nl) * | 1969-03-26 | 1973-05-15 | Erba Carlo Spa | Werkwijze voor het bereiden van benzeensulfonylureumderivaten met bloedsuikerspiegelverlagende werking. |
| NL7314765A (ko) * | 1972-10-31 | 1974-05-02 | ||
| DE2657382A1 (de) * | 1976-12-17 | 1978-06-29 | Thera Ges Fuer Patente | Orales antidiabetikmittel |
| EP0045238B1 (en) * | 1980-07-29 | 1986-10-01 | Sanofi S.A. | Acid stabilized compositions of thieno-pyridine derived compounds and process for preventing degradation of such compounds |
| US4430399A (en) * | 1980-09-25 | 1984-02-07 | Duracell Inc. | Method of electrode formation and article |
| DE3100535A1 (de) * | 1981-01-10 | 1982-08-12 | Dr. Karl Thomae Gmbh, 7950 Biberach | "neue carbonsaeure-derivate, ihre herstellung und ihre verwendung als arzneimittel" |
| DE3225188A1 (de) * | 1982-07-06 | 1984-01-12 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue phenylessigsaeurederivate, ihre herstellung und diese verbindungen enthaltende arzneimittel |
| DE3124090A1 (de) * | 1981-06-19 | 1983-01-05 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue orale dipyridamolformen |
| DE3126703A1 (de) * | 1981-07-07 | 1983-01-27 | Dr. Karl Thomae Gmbh, 7950 Biberach | Bromhexin-retardform und verfahren zu ihrer herstellung |
| GB2118040A (en) * | 1982-02-15 | 1983-10-26 | Hoechst Uk Ltd | Oral anti-diabetic preparation |
| DE3320582A1 (de) * | 1983-06-08 | 1984-12-13 | Dr. Karl Thomae Gmbh, 7950 Biberach | Gliquidonhaltige zubereitungsformen und verfahren zu ihrer herstellung |
-
1983
- 1983-06-08 DE DE19833320582 patent/DE3320582A1/de not_active Ceased
-
1984
- 1984-05-31 US US06/615,892 patent/US4696815A/en not_active Expired - Fee Related
- 1984-06-01 DE DE8484106272T patent/DE3483175D1/de not_active Expired - Fee Related
- 1984-06-01 AT AT84106272T patent/ATE56365T1/de not_active IP Right Cessation
- 1984-06-01 EP EP84106272A patent/EP0128483B1/de not_active Expired - Lifetime
- 1984-06-05 IL IL72034A patent/IL72034A/xx unknown
- 1984-06-06 GR GR74942A patent/GR82362B/el unknown
- 1984-06-06 DD DD84263871A patent/DD224216A5/de not_active IP Right Cessation
- 1984-06-07 DK DK281184A patent/DK162019C/da not_active IP Right Cessation
- 1984-06-07 NO NO842290A patent/NO168628C/no unknown
- 1984-06-07 JP JP59117432A patent/JPS6069038A/ja active Granted
- 1984-06-07 KR KR1019840003188A patent/KR910004571B1/ko not_active IP Right Cessation
- 1984-06-07 GB GB08414529A patent/GB2142236B/en not_active Expired
- 1984-06-07 ES ES533208A patent/ES8506446A1/es not_active Expired
- 1984-06-07 NZ NZ208417A patent/NZ208417A/en unknown
- 1984-06-07 CA CA000456096A patent/CA1228299A/en not_active Expired
- 1984-06-07 HU HU842206A patent/HU193932B/hu not_active IP Right Cessation
- 1984-06-07 IE IE1423/84A patent/IE57793B1/en not_active IP Right Cessation
- 1984-06-07 ZA ZA844296A patent/ZA844296B/xx unknown
- 1984-06-07 FI FI842294A patent/FI85217C/fi not_active IP Right Cessation
- 1984-06-08 PH PH30794A patent/PH24567A/en unknown
- 1984-06-08 PT PT78710A patent/PT78710B/pt unknown
- 1984-06-08 AU AU29240/84A patent/AU563642B2/en not_active Ceased
-
1987
- 1987-05-30 SG SG48187A patent/SG48187G/en unknown
- 1987-07-06 MY MYPI87000951A patent/MY100795A/en unknown
- 1987-07-23 US US07/076,697 patent/US4863724A/en not_active Expired - Lifetime
- 1987-10-07 HK HK723/87A patent/HK72387A/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR850000240A (ko) | 경구용 당뇨병 치료제 제형의 제조방법 | |
| US4153689A (en) | Stable insulin preparation for nasal administration | |
| US4937267A (en) | Method of treatment of obesity | |
| DZ1067A1 (fr) | Nouvelles préparations pharmaceutiques à emission prolongée. | |
| ATE31411T1 (de) | Piperazin-derivate, verfahren zu ihrer herstellung und diese als aktive bestandteile enthaltende pharmazeutische zusammensetzungen. | |
| PT715856E (pt) | Composição antifúngica armazenável em queratina para utilização externa | |
| IL83044A (en) | Diphenylpropanamines,their preparation and pharmaceutical compositions containing them | |
| ES2052028T3 (es) | Un metodo para preparar compuestos diarilicos anti-ateroscleroticos. | |
| US4777047A (en) | Transdermal application form of calcium antagonists | |
| KR830003462A (ko) | 치환된 옥시란 카르복실릭 산류의 제조방법 | |
| RU94026094A (ru) | Применение феналкиламинов | |
| KR900016135A (ko) | 피부 및 점막-상피의 질환 치료용 4-퀴놀린 카복실산 유도체 | |
| AR002260A1 (es) | Compuestos derivados de acido [4-(indazol-3-il)-piperidin-1-il]-acetico, procedimiento para su preparacion, composicion farmacuetica que los contienen,el uso de los mismos en la preparacion de un agente terapeutico, metodo de tratamiento y compuestos intermediarios. | |
| ATE55248T1 (de) | Arzneimittelkombination. | |
| FI95348C (fi) | Menetelmä suun kautta annettavan nestemäisen koostumuksen valmistamiseksi | |
| NO910304L (no) | Nye leukotrien-b4-derivater, fremgangsmaate for deres fremstilling og deres anvendelse som legemiddel. | |
| ATE28862T1 (de) | Aktive kompositionen gegen motten, weisse fliegen und holzwuermer, pharmazeutische kompositionen und benzoylharnstoffderivaten. | |
| ES2055248T3 (es) | Estabilizacion de emulsiones de perfluorocarbono y compuestos heterociclicos perfluorados utilizables como adiciones estabilizadoras de emulsiones. | |
| KR860000269A (ko) | 칼슘길항성의 1-[비스-(4-플루오로페닐)-메틸-4-(3-페닐-2-프로페닐)-헥사하이드로-1h-1, 4-디아제핀의 제조방법및 이것을 함유한 약학적조성물 | |
| KR890006621A (ko) | 항불안제 | |
| JPH11189531A (ja) | 経粘膜投与用医薬組成物 | |
| KR910009257A (ko) | 이펜프로딜 및 그의 유도체를 유효성분으로 하는 정신병치료제 | |
| SE8004383L (sv) | Farmaceutisk beredning for oral administrering och forfarande for dess framstellning | |
| KR880004810A (ko) | 소화성 궤양 치료제 | |
| KR930019212A (ko) | 피소스티그민 유도체와 이의 용도 및 이를 함유한 제약적 조제물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| G160 | Decision to publish patent application | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20020621 Year of fee payment: 12 |
|
| LAPS | Lapse due to unpaid annual fee |